Tripos and Chronogen Announce a Drug Discovery Partnership

Tripos to Provide Complete Drug Discovery Chemistry Services to Chronogen

Tripos, Inc. and Chronogen Inc. announced a three-year collaboration to discover and optimize small-molecule therapeutics for cardiovascular disorders. Under the agreement, Tripos will employ its knowledge-driven chemistry process to provide complete drug discovery chemistry services for Chronogen. Drawing upon its proprietary chemical libraries, expertise in data analysis, design tools and rapid synthetic follow-up capabilities, Tripos will support Chronogen's biological expertise in metabolic pathways related to aging. Chronogen will apply its proprietary in vivo screening technologies to rapidly select effective molecules, and Tripos will collaborate with Chronogen to optimize them for specific cardiovascular indications.

Other news from the department science

Most read news

More news from our other portals

Under the magnifying glass: The world of microscopy